ABSTRACT

Introduction:

Status epilepticus is an important part of pediatric intensive care hospitalizations. In this study, it was aimed to investigate the general characteristics and to share the clinical and demographical features of patients who were hospitalized due to convulsive status epilepticus.

Methods:

One hundred-thirty one cases were included in this study. Identity information of patients, presence of acute and chronic diseases, duration of intensive care stay and hospitalization, first seizure type, where they were admitted, number of seizures during intensive care follow-up, antiepileptics used in treatment and other treatments and the status of discharge-mortality were recorded.

Results:

62.6% of cases were male and the mean age of all cases was 53.69±47.14 months. The most common chronic disease was epilepsy and the most common acute disease was lower respiratory tract infection. The first admission of 34.4% of the cases was due to status epilepticus, and the rate of cases accepted from other hospitals was 60.3%. During intensive care follow-up, no convulsions were observed in 77.1% of the cases. In the first treatment, benzodiazepine infusion was used in 77.1% of the cases. The median length of stay in intensive care unit was 4 days (minimum-maximum= 3-8 days) in the benzodiazepine infusion group, and 3 days (minimum-maximum=2-3 days) in the group that was not given benzodiazepine. The other most preferred antiepileptics were levetiracetam and phenytoin in 62.6% and 39.7% of the cases, respectively. The mortality rate was found as 2.3%.

Conclusion:

In our study, it was observed that the majority of the patients who were hospitalized in our pediatric intensive care unit due to convulsive status epilepticus were male, convulsive status epilepticus was more common in children with chronic neurological disease, benzodiazepine infusion was the first choice for treatment and Levetiracetam was the second most commonly used antiepileptic.

Keywords: Benzodiazepine, child, phenobarbital, levetiracetam, status epilepticus

References

Riviello JJ. Pediatric status epilepticus: Initial management and the special syndromes of status epilepticus in children. In:Drislane FW, Kaplan MBBS, Peter W (eds). Status epilepticus: a clinical perspective. 2nd ed. Humana Press; 2018:333-52.

Trinka E, Cock H, Hesdorffer D, Rossetti AO, Scheffer IE, et al. A definition and classification of status epilepticus- report of the ILAE task force on classification of status epilepticus. Epilepsia. 2015;56:1515-23.

Mikati MA, Hani AJ. Status epilepticus. In:Kliegman RM, Behrman RE, Jenson HB, Stanton FB (eds). Nelson Textbook of Pediatrics. 20th ed. Philadelphia: Saunders; 2016:2854-6.

DeLorenzo RJ, Hauser WA, Towne AR, Boggs JG, Pellock JM, et al. A prospective, population-based epidemiologic study of status epilepticus in Richmond, Virginia. Neurology. 1996;46:1029-35.

Brophy GM, Bell R, Claassen J, Alldredge B, Bleck TP, et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care. 2012;17:3-23.

Glauser T, Shinnar S, Gloss D, Alldredge B, Arya R, et al. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the Guideline Committee of the American Epilepsy Society. Epilepsy Curr. 2016;16:48-61.

Erkek N, Öztürk N, Şevketoğlu E. Status Epilepticus Tedavi Protokolü. Çocuk Acil ve Yoğun Bakım Derneği Web site. Ulaşılabilir:http://www.cayd.org.tr/gorseller/files/protokoller/C%CC%A7AYD%20Status%20Epileptikus%20protokolu%CC%88%20(01022018).pdf. 2017.

Asadi-Pooya A, Poordast A. Etiologies and outcomes of status epilepticus in children. Epilepsy & Behavior. 2005;3:502-5.

Incecik F, Horoz OO, Herguner OM, Yıldızdas D, Besen S, et al. Intravenous levetiracetam in critically ill children. Ann Indian Acad Neurol. 2016;19:79‑82.

İşgüder R, Guzel O, Ağın H, Yılmaz Ü, Akarcan SE, et al. Efficacy and safety of intravenous levetiracetam in children with acute repetitive seizures. J Pediatr Neurol. 2014;51:688‑95.

Berg AT, Shinnar S, Testa FM, Levy SR, Frobish D, et al. Status epilepticus after the initial diagnosis of epilepsy in children. Neurology. 2004;63:1027.

Haut SR, Shinnar S, Moshé SL, O’Dell C, Legatt AD. The association between seizure clustering and convulsive status epilepticus in patients with intractable complex partial seizures. Epilepsia. 1999;40:1832.

Shinnar S, Berg AT, Moshe SL, O’Dell C, Alemany M, et al. The risk of seizure recurrence after a first unprovoked afebrile seizure in childhood: an extended follow-up. Pediatrics. 1996;98:216-25.

Au CC, Branco RG, Tasker RC. Management protocols for status epilepticus in the pediatric emergency room: systematic review article. J Pediatr. 2017;93:84-94.

Alford EL, Wheless JW, Phelps SJ. Treatment of generalized convulsive status epilepticus in pediatric patients. The Journal of Pediatric Pharmacology and Therapeutics. 2015;20:260-89.

Rivera R, Segnini M, Baltodano A, Pérez V. Midazolam in the treatment of status epilepticus in children. Crit Care Med. 1993;21:991-4.

Ulusoy E, Duman M, Türker HD. The effect of early midazolam infusion on the duration of pediatric status epilepticus patients. Seizure. 2019;71:50-5.

Lyttle MD, Rainford NEA, Gamble C, Messahel S, Humphreys A, et al. Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial. Lancet. 2019;393:2125-34.

Kapur J, Elm J, Chamberlain JM, Barsan W, Cloyd J, et al. Randomized trial of three anticonvulsant medications for status epilepticus. N Engl J Med. 2019;381:2103-13.

Lee YJ, Yum MS, Kim EH, Ko TS. Intravenous levetiracetam versus phenobarbital in children with status epilepticus or acute repetitive seizures. Korean J Pediatr. 2016;59:35-9.

Yasiry Z, Shorvon SD. The relative effectiveness of five antiepileptic drugs in treatment of benzodiazepine-resistant convulsive status epilepticus: a meta-analysis of published studies. Seizure. 2014;23:167-74.

Fernandez IS, Gainza-Lein M, Lamb N, Loddenkemper T. Meta-analysis and cost-effectiveness of second-line antiepileptic drugs for status epilepticus. Neurology. 2019;92:2339-48.

Malamiri RA, Ghaempanah M, Khosroshahi N, Nikkhah A, Bavarian B, et al. Efficacy and safety of intravenous sodium valproate versus phenobarbital in controlling convulsive status epilepticus and acute prolonged convulsive seizures in children: a randomised trial. Eur J Paediatr Neurol. 2012;16:536-41.

Specchio N, Pietrafusa N, Bellusci M, Trivisano M, Benvenga A, et al. Pediatric status epilepticus: Identification of prognostic factors using the new ILAE classification after 5 years of follow-up. Epilepsia. 2019;60:2486-98.

Asadi-Pooya AA, Poordast A. Etiologies and outcomes of status epilepticus in children. Epilepsy Behav. 2005;7:502-5.

Eriksson K, Koivikko M. Status epilepticus in children: aetiology, treatment, and outcome. Dev Med Child Neurol. 1997;39:652-8.

Jafarpour S, Stredny CM, Piantino J, Chapman KE. Baseline and outcome assessment in pediatric status epilepticus. Seizure. 2019;68:52-61.

Evaluation of Clinical and Demographic Characteristics of Patients Hospitalized in the Pediatric Intensive Care Unit due to Convulsive Status Epilepticus

ABSTRACT

References